The World Health Organization (WHO) is pausing the hydroxycholoroquine arm of its global COVID-19 drug trials after a review found the malaria therapy was associated with raised death rates and heart problems.
Coronavirus Update: WHO Suspends Hydroxychloroquine Trial, Novavax Launches Phase I/II Vaccine Study
Plus: Medicago Plans Vaccine Trials After Positive Early Results
Mounting evidence that President Trump's 'game changer' does more harm than good for COVID-19 patients. Novovax and Medicago among the latest vaccine developers to report progress.
More from COVID-19
More from Scrip
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.